ArticleeLife2018
Kasugamycin potentiates rifampicin and limits emergence of resistance in
Abstract read
In one paragraph
Article in eLife, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Article
- Transcription attenuation amplifies collateral vulnerabilities in rifampicin-resistant Mycobacterium tuberculosis.Nature microbiology · 2026Article
- Beyond Inhibition: Sublethal Rifampicin-Induced Molecular Adaptations Confer Phenotypic Drug Tolerance in Mycobacteria.ACS infectious diseases · 2026Article
- Ribosomal RNA methylation by GidB modulates discrimination of mischarged tRNA.bioRxiv : the preprint server for biology · 2026Article
- Profiling of BDQ-induced transcriptome suggests amino acid metabolism and stress responses as alternate mechanisms contributing to BDQ tolerance inMicrobiology spectrum · 2026Article
- Kasugamycin Inhibits Melanoma Lung Metastasis and CHI3L1-Driven M2-Like Tumor-Associated Macrophage Differentiation.ImmunoTargets and therapy · 2026Article
- Article
- Anti-tuberculosis treatment strategies and drug development: challenges and priorities.Nature reviews. Microbiology · 2022Review
- Kasugamycin Is a Novel Chitinase 1 Inhibitor with Strong Antifibrotic Effects on Pulmonary Fibrosis.American journal of respiratory cell and molecular biology · 2022Article
- The context of the ribosome binding site in mRNAs defines specificity of action of kasugamycin, an inhibitor of translation initiation.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- KasQ an Epimerase Primes the Biosynthesis of Aminoglycoside Antibiotic Kasugamycin and KasF/H Acetyltransferases Inactivate Its Activity.Biomedicines · 2022Article
- Ribosome profiling enhances understanding of mycobacterial translation.Frontiers in microbiology · 2022Review
- Rifamycin antibiotics and the mechanisms of their failure.The Journal of antibiotics · 2021Review
- Clinically Relevant Mutations of Mycobacterial GatCAB Inform Regulation of Translational Fidelity.mBio · 2021Article
- Heterogeneous Host-Pathogen Encounters Coordinate Antibiotic Resilience in Mycobacterium tuberculosis.Trends in microbiology · 2021Review
- Most-Probable-Number-Based Minimum Duration of Killing Assay for Determining the Spectrum of Rifampicin Susceptibility in Clinical Mycobacterium tuberculosis Isolates.Antimicrobial agents and chemotherapy · 2021Article
- Selective translation by alternative bacterial ribosomes.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Tissue Distribution of Doxycycline in Animal Models of Tuberculosis.Antimicrobial agents and chemotherapy · 2020Article
- Antitubercular Triazines: Optimization and Intrabacterial Metabolism.Cell chemical biology · 2020Article
- Highly Contingent Phenotypes of Lon Protease Deficiency in Escherichia coli upon Antibiotic Challenge.Journal of bacteriology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Swarnava Chaudhuri *Centre for Global Health and Infectious Diseases, Collaborative Innovation Centre for the Diagnosis and Treatment of Infectious Diseases, Tsinghua University School of Medicine, Beijing, China.
Liping Li *Public Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, United States.
Matthew ZimmermanPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, United States.
Yuemeng ChenCentre for Global Health and Infectious Diseases, Collaborative Innovation Centre for the Diagnosis and Treatment of Infectious Diseases, Tsinghua University School of Medicine, Beijing, China.
Yu-Xiang ChenCentre for Global Health and Infectious Diseases, Collaborative Innovation Centre for the Diagnosis and Treatment of Infectious Diseases, Tsinghua University School of Medicine, Beijing, China.
Melody N TooskyCentre for Global Health and Infectious Diseases, Collaborative Innovation Centre for the Diagnosis and Treatment of Infectious Diseases, Tsinghua University School of Medicine, Beijing, China.
Michelle GardnerDepartment of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, United States.
Miaomiao PanCentre for Global Health and Infectious Diseases, Collaborative Innovation Centre for the Diagnosis and Treatment of Infectious Diseases, Tsinghua University School of Medicine, Beijing, China.
Yang-Yang LiCentre for Global Health and Infectious Diseases, Collaborative Innovation Centre for the Diagnosis and Treatment of Infectious Diseases, Tsinghua University School of Medicine, Beijing, China.
Qingwen KawajiCentre for Global Health and Infectious Diseases, Collaborative Innovation Centre for the Diagnosis and Treatment of Infectious Diseases, Tsinghua University School of Medicine, Beijing, China.
Jun-Hao ZhuCentre for Global Health and Infectious Diseases, Collaborative Innovation Centre for the Diagnosis and Treatment of Infectious Diseases, Tsinghua University School of Medicine, Beijing, China.
Hong-Wei SuCentre for Global Health and Infectious Diseases, Collaborative Innovation Centre for the Diagnosis and Treatment of Infectious Diseases, Tsinghua University School of Medicine, Beijing, China.
Amanda J MartinotCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, United States.
Eric J RubinDepartment of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, United States.ORCID http://orcid.org/0000-0001-5120-962X
Veronique Anne DartoisPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, United States.ORCID https://orcid.org/0000-0001-9470-5009
Babak JavidCentre for Global Health and Infectious Diseases, Collaborative Innovation Centre for the Diagnosis and Treatment of Infectious Diseases, Tsinghua University School of Medicine, Beijing, China.ORCID http://orcid.org/0000-0002-6354-6305
Funding
High-Throughput TB Vaccine Antigen DiscoveryK08AI135098 · NIAID · TUFTS UNIVERSITY BOSTON · PI MARTINOT, AMANDA · 2018 to 2022
$931kA QTRAP 6500 LC-MS/MS System from SCIEX for high accuracy drug content analysisS10OD023524 · OD · RBHS-NEW JERSEY MEDICAL SCHOOL · PI DARTOIS, VERONIQUE · 2017 to 2017
$526kBill and Melinda Gates Foundation OPP1109789National Natural Science Foundation of China 31570129NIAID NIH HHS K08 AI135098NIH HHS S10 OD023524Wellcome 207487/B/17/ZWellcome TrustWellcome Trust 207487/B/17/Z
Abstract
Most bacteria use an indirect pathway to generate aminoacylated glutamine and/or asparagine tRNAs. Clinical isolates of
Indexed as
AminoacylationAminoglycosidesAnimalsDrug Resistance, BacterialDrug SynergismEdeineInjections, IntraperitonealMiceMicrobial Sensitivity TestsMycobacterium tuberculosisOrgan SpecificityProtein BiosynthesisRifampinRNA, TransferStreptomycinTuberculosisAminoglycosidesEdeinekasugamycinRifampinRNA, TransferStreptomycinantibiotic toleranceinfectious diseasekasugamycinmicrobiologymistranslationmouseMycobacterium tuberculosispersister
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.